1	COVID-19 Outcomes and Genomic characterization of SARS-CoV-2 isolated from
2	Veterans in New England States
3	Megan Lee, BS ^{1*} ; Ya Haddy Sallah, MPH ^{1*} ; Mary E. Petrone, BS ^{2*} ; Matthew Ringer, MD ³ ;
4	Danielle Cosentino, BS ⁴ ; Chantal B.F. Vogels, PhD ² ; Joseph R. Fauver, PhD ² ; Tara Alpert,
5	PhD ² ; Nathan D. Grubaugh, PhD ² ; Shaili Gupta, MBBS ^{3,5}
6	¹ Yale School of Medicine, 333 Cedar St., New Haven, CT 06511
7	² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, 60 College
8	St, New Haven, CT 06510
9	³ Department of Internal Medicine, Yale School of Medicine, 333 Cedar St, New Haven, CT
10	06510
11	⁴ Department of Clinical Informatics, AV Connecticut Healthcare System, 950 Campbell Ave,
12	West Haven, CT 06516
13	⁵ Department of Medicine, VA Connecticut Healthcare System, 950 Campbell Ave, West Haven,
14	CT 06516
15	* M.L., Y.H.S. and M.E.P. contributed equally to this work and are co-first authors.
16 17	Running Title: COVID-19 Outcomes and SARS-CoV-2 lineages in New England Veterans
18	Corresponding Author:
19	Shaili Gupta, MBBS
20	Department of Medicine, Yale School of Medicine
21	VA Connecticut Healthcare System
22	950 Campbell Ave, Bldg 1, 5 th floor, Mailstop 111
23	West Haven, CT 06516
24	E-mail: shaili.gupta@yale.edu; phone: 203-932-5711, ext 4412; fax: 203-932-3748
25	Word count: Abstract: 250. Main text: 2,037.

26 Abstract:

27

Background: Clinical and virologic characteristics of COVID-19 infections in veterans in New
England have not been described.

30 **Objectives:** To evaluate clinical and virologic factors impacting COVID-19 outcomes.

31 Study Design: We reviewed charts and sequenced virus from nasopharyngeal specimens with

32 confirmed SARS-CoV-2 from 426 veterans in six New England states between April and

33 September, 2020. Peak disease severity, hospitalization, and mortality were correlated to clinical,

34 demographic, and virologic factors.

35 **Results**: Of 426 veterans, 274 had complete and accessible charts. 92.7% were men, 83.2%

36 White, with mean age 63 years. On multivariate regression, significant predictors of

37 hospitalization were age (OR: 1.05) and non-white race (OR: 2.39). Mortality and peak disease

38 severity varied by age (OR 1.06 and 1.07 respectively) and oxygen requirement on admission

39 (OR6.74 and 45.7). Dementia (OR: 3.44) was also associated with mortality. Most (97.3%) of

40 our samples were dominated by the spike protein D614G substitution, and were from SARS-

41 CoV-2 B.1 lineage or one of 37 different B.1 sub-lineages, with none representing more than

42 8.7% of the cases.

43 **Conclusions**: In an older cohort of veterans from the six New England states with a high

44 comorbidity burden, age was the largest predictor of hospitalization, peak disease severity, and

45 mortality. Non-white veterans were more likely to be hospitalized, and patients who required

46 oxygen on admission were more likely to have severe disease and higher rates of mortality.

47 Multiple SARS-CoV-2 lineages were distributed in patients in New England early in the

48 COVID-19 era, mostly related to viruses from New York with D614G mutation.

49 Keywords: COVID-19, Outcomes, Veterans, Age, SARS-CoV-2, D614G

51 Background

52 The Coronavirus Disease 2019 (COVID-19) caused by Severe Acute Respiratory 53 Syndrome Coronavirus-2 (SARS-CoV-2) has infected >30 million people in the United States 54 and caused nearly 600,000 deaths [1]. Disease severities and outcomes vary among individuals 55 who become infected. Throughout the course of the pandemic, researchers have tried to identify 56 patient and viral characteristics that predispose patients to having worse outcomes. Some host-57 factors known to impact disease severity and mortality include Charlson comorbidity index 58 score, age, and body mass index (BMI) [2-6]. 59 Virologic characteristics have also been suggested to impact the severity of disease. 60 A dynamic nomenclature system (Pangolin) was developed to classify SARS-CoV-2 and identify 61 lineages and mutations that could impact could impact infectivity and virulence [7]. Early during 62 the pandemic course in the United States, viral isolates on the East Coast of the US were 63 predominantly of the B.1 lineage that contained the Spike protein D614G substitution [8]. This 64 substitution has been suggested to have higher transmissibility [9], supported by the higher upper 65 airway viral loads and higher viral replication in lung epithelial cells [10]. At the same time, 66 viruses with the D614G substitution has also been found to be more susceptible to neutralization 67 by antibodies generated by infection with wild-type virus [11,12]. With the increasing focus on 68 emerging SARS-CoV-2 genetic variants, such as the lethality of B.1.1.7 [13], more research is 69 required on how mutations affect patient outcomes. Furthermore, understanding viral 70 epidemiology and a regional evaluation of viral variants, with their respective clinical 71 correlations, is important to provide a full understanding of the disease. 72

74 **Objectives**

Given the high variability and conflicting data in predicting who will have poor outcomes, assessment of specific populations is necessary to give providers the best clinical picture on their patients. Clinical outcomes of veterans with COVID-19 in New England and respective SARS-CoV-2 genomics have not been described. We aimed to (1) describe patient characteristics, comorbidities, and disease factors that impact patient outcomes and (2) present data on the genomic composition of the SARS-CoV-2 infecting these patients. Factors impacting outcomes help inform triage and management algorithms for COVID-19.

82

83 Study Design

84 Our cohort was composed of all veterans receiving care at Veterans Administration (VA) 85 healthcare centers who tested positive in six New England states (Connecticut, Massachusetts, 86 Maine, New Hampshire, Rhode Island, Vermont) from April 8, 2020, to September 16, 2020. 87 Inclusion criteria included patients with accessible chart records and a positive COVID-19 test. 88 We manually reviewed charts and recorded demographics [age, gender, race, body-mass index 89 (BMI), long-term care facility (LTC) status, and state of residence when diagnosed with COVID-90 19]. Comorbidities recorded were immunosuppression, dementia, diabetes mellitus, chronic 91 kidney disease (CKD) stage \geq 3, chronic liver disease, coronary artery disease (CAD), heart 92 failure, atrial fibrillation (aFib), chronic obstructive pulmonary disease (COPD), asthma, and 93 active tobacco use. A clinical database repository and virologic repository was created for all 94 veterans diagnosed with COVID-19 in the VA healthcare system of New England, and was 95 approved by VA Connecticut Institutional Review Board. Whole genome sequencing was

96	conducted on SARS-CoV-2 isolates with a cycle threshold (Ct) value <36, and provided near-
97	complete or complete genome results where Ct value was <30.
98	We recorded hospitalization status of patients, mortality, and whether patients required
99	oxygen (O2) within 24 hours of admission. Lastly, we divided patients based on their peak
100	disease severity into five categories depending on oxygenation requirements: 1) no O2
101	requirement, 2) 1-3 liters (L) by nasal cannula (NC), 3) 4-6 L NC, 4) >6 L O2 or non-invasive
102	positive pressure ventilation (NIPPV), and 5) mechanical ventilation. We used STATA v16 for
103	univariate and multivariate logistic regressions to predict the outcomes of interest.
104	For the genetic data, we sequenced whole virus genomes ($\geq 20x$ coverage depth across
105	\geq 70% of the genome) using Illumina (n = 238) and Nanopore (n = 61) platforms. Using BWA-
106	MEM version 0.7.15, we aligned reads to the Wuhan-Hu-1 reference genomes (GenBank
107	MN908937.3). With iVar v1.2.1, we trimmed sequencing adaptors and primer sequences and
108	called bases by simple majority (>50% frequency) at each site to generate consensus genomes.
109	An ambiguous N was used when fewer than 10 reads were present at a site. We aligned these
110	consensus genomes with MAFFT [14], and masked problematic sites [15]. We then built a
111	phylogenetic tree with IQTree [16] using an HKY substitution model and 1000 bootstraps. We
112	visualized this tree using the Python module baltic v0.1.5. We used Pangolin to assign lineages
113	to our genomes [7].
114	

Results

Of 476 veterans in six New England states with confirmed SARS-CoV-2 during the study
period, 274 had complete and accessible charts. Of 274 veterans, 92.7% were men, 83.2% White,
and mean age was 63 years (standard deviation: 17.6 years) (Table 1). Over a third resided in

LTC (n=92), of which 76% were at the VA's community living center. Over half the residents
were from Massachusetts, and one third from Connecticut. The most common comorbidities
were CAD (27%), diabetes (25%), and tobacco use (23%).

122 Notably, 11.7% patients required O2 above their baseline home oxygen requirements 123 within 24 hours of admission, and 20.8% of all patients required oxygen support at some point 124 during hospitalization. In terms of peak severity, 78.5% required only room air, 10.9% required 125 1-3 L O2 via NC, 4.0% required 4-6 L O2 via NC, 3.6% required >6L O2 or NIPPV, and 2.2% 126 were intubated. The hospitalization rate was 28.8% (Figure 1), with the highest rates in people 127 with COPD (50%), CAD (45.9%), and those over age 80 years (44.4%). The overall mortality 128 rate was 10.6% (Figure 2), with the highest rates in people with dementia (33.3%), age >80 129 (28.9%), and those from LTC (23.9%).

130 In univariate regressions, significant predictors of hospitalization were age (Odds Ratio

131 (OR), 95% confidence interval (CI): 1.06), non-White race (OR: 1.97), LTC residence (OR:

132 1.78), COPD (OR: 3.04), CAD (OR: 2.93), and aFib (OR: 2.05). Peak severity increased with

133 age (OR: 1.06), LTC residence (OR: 2.8), CAD (OR: 2.1), aFib (OR: 2.97), and O2 requirement

134 on admission (OR: 46.2). Higher mortality was seen with age (OR: 1.10), LTC residence (OR:

135 7.86), BMI<30 (OR: 5.80), dementia (OR: 7.23), aFib (OR: 3.11), hospitalization (OR: 2.58),

and O2 requirement on admission (OR: 4.34) (Table 2).

137 Using multivariate regression, significant predictors of hospitalization were age (OR:

138 1.05) and non-White race (OR: 2.39) (Table 3). Peak severity also varied by age (OR: 1.07) and

139 O2 requirement on admission (OR: 45.7). Mortality was predicted by age (OR: 1.06), dementia

140 (OR:3.44), and O2 requirement on admission (OR: 6.74). In other words, for every year increase

in age, the odds of hospitalization increased by 5%, peak severity increased by 7%, and mortalityincreased by 6%.

143	For the genomic characteristics, amongst the 426 patients, 299 patients genomes had
144	adequate coverage for analysis. We found the majority of our specimens (154/299, 51.5%) were
145	from SARS-CoV-2 lineage B.1, or a sub-lineage of B.1 (e.g. B.1.302, B.1.303, B.1.356;
146	137/299, 45.8%), all of which are defined by D614G substitution (Figure 3, Appendix Table 1).
147	Only 2.4% (7/299) were from the lineage A that lack the D614G mutation. Since there were 41
148	SARS-CoV-2 lineages detected in our cohort, with none of the sub-lineages consisting of more
149	than 26 COVID-19 cases, we did not have the power to test for clinical correlates. Our
150	sequencing data does inform us that the outcomes presented in this VA cohort are dominated by
151	the impacts, whatever they may be, of the B lineage D614G mutation.

152

153 Discussion

154 Our study found that in an older cohort of veterans with a high comorbidity burden, age 155 significantly associated with of hospitalization, peak disease severity, and mortality. Our study is 156 unique in that it is the first to look at several COVID-19 outcomes in veterans from the six New 157 England states. The CDC currently has a list of chronic medical conditions that predispose 158 individuals to severe illness from SARS-CoV-2 infection [17]. This comprehensive list of 159 comorbidities can be difficult to interpret, however, and one study found that >75% of United 160 States adults would fall under a high-risk category [18]. Veterans are a unique cohort because 161 they suffer from high rates of comorbid disease and advanced age. Understanding clinical factors 162 that impact outcomes in veterans will help clinicians risk-stratify patients with similar 163 demographic profiles.

164 Many COVID-19 studies have found age to be a predictor of worse outcomes [4,19-22]. 165 In our study, age was a significant predictor for all of our outcomes and was a confounder for 166 other variables. Interestingly, LTC status predicted all three of our outcomes on univariate 167 analysis, but not on multivariate analyses. Because age is associated with both having COVID-168 19 and living in an LTC, it confounded the relationship between the outcomes and LTC status. 169 Earlier in the COVID-19 pandemic, residents of nursing homes had higher rates of infection as 170 well as severe illness and mortality [23]. Our study shows that among veterans in LTC facility, 171 disease outcomes were not impacted by their residence status. 172 Concurrent work in our lab suggests that oxygen requirement on admission predicts poor 173 outcomes in veterans (Ringer et al, unpublished work). This has helped inform the triage 174 guidelines at our healthcare system. This is an important finding because other ways of 175 determining oxygenation status, such as the arterial oxygen saturation/ fraction of inspired 176 oxygen (SaO2/FiO2) ratio [24], can frequently change, and thus become difficult for clinicians to 177 use in practice. 178 Our study supports data from previous trials that non-White patients are at increased risk 179 of hospitalization but have similar peak severity and mortality outcomes [25,26]. One study of 180 5,902 patients with COVID-19 in New York found that non-Hispanic Black patients were more 181 likely to test positive for coronavirus but had similar outcomes [27]. Similar to our study, Azar et 182 al. found that in 1052 cases of COVID-19 in California, non-Hispanic African American patients 183 had 2.7 increase in odds of being hospitalized [28]. Cardemil et al. also found a 4.6 and 4.2-fold 184 increase in rates of hospitalization for Hispanic and Black veterans, respectively.[25] Many 185 studies have shown that minorities often have delays in care due to mistrust of the medical

186 system because of providers' implicit biases [29,30], which might explain the outcomes in our

study. It is critical to continue ongoing efforts to combat medical inequities and target preventionefforts and education to communities and racial groups most affected by COVID-19.

189 After adjusting for age and other comorbidities, we found that patients with dementia had 190 a higher risk of death. This is similar to other studies on patients with COVID-19 and dementia 191 [20,31,32]. In a meta-analysis of 46,391 patients, Hariyanto et al. found that dementia was 192 associated with a higher risk of severe infection (relative risk: 2.63) and death (relative risk: 193 2.62) [33]. This may be explained by a host of biological factors, but it emphasizes the 194 importance of extra care and monitoring required when approaching a patient with dementia. In 195 this vulnerable population, providers and caregivers must ensure they receive sufficient support 196 throughout the course of their illness.

197 Limitations of this work include the smaller sample size. Furthermore, our study is 198 specific to veterans, which is a largely male and older cohort, and results may not therefore be 199 generalizable. The time period of this study was prior to established medical therapies for 200 COVID-19 and our outcomes reported are likely worse than you would expect today. Since this 201 was during the first wave of the pandemic when standard guidelines were not yet solidified, 202 many patients not requiring oxygen were admitted which is not standard of practice today. 203 Strengths of our study include its comprehensive scope, wide geographic range, manual chart 204 review allowing for the capturing of all comorbidities and oxygenation parameters that may not 205 be available otherwise in a database, and multivariate analysis of many potential risk factors.

206

207 Conclusion

208 Our study found that in an older cohort of veterans from the six New England states with a high 209 comorbidity burden, age was the single strongest predictor of hospitalization, peak severity, and

- 210 mortality. Non-white veterans were more likely to be hospitalized, and patients who required
- 211 oxygen on admission were more likely to have severe disease and higher rates of mortality.
- 212 Furthermore, patients with dementia were more likely to die. Multiple genomic variants of
- 213 SARS-CoV-2 were distributed in patients in New England early in the COVID-19 era, mostly
- from a B.1 sub-lineage with the spike D614G mutation.
- 215

216	Acknowledgements: The authors report no conflicts of interest.
217	Funding: This work was supported by Centers for Disease Control and Prevention [BAA
218	75D301-20-R-68024 to N.D.G. and S.G.] and the Yale Center for Clinical Investigation TL1
219	TR001864 (M.E.P.).
220	
221	
222	
223	
224	
225	
226	
227	
228	
229	
230	
231	
232	
233	
234	
235	
236	
237	
238 239	

240		
240 241		
241		
242 243		Literature Cited
243 244		Literature Cited
244 245	1.	U.S. Department of Health & Human Services. Published COVID Data Tracker.
243 246	1.	Accessed March 25, 2021.
240 247	2.	Simonnet A, Chetboun M, Poissy J, et al. High Prevalence of Obesity in Severe Acute
247	2.	Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Requiring Invasive Mechanical
248 249		Ventilation. <i>Obesity (Silver Spring)</i> . 2020;28(7):1195-1199.
249	3.	Garg S, Kim L, Whitaker M, et al. Hospitalization Rates and Characteristics of Patients
250 251	5.	Hospitalized with Laboratory-Confirmed Coronavirus Disease 2019 - COVID-NET, 14
251		States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-464.
252 253	4.	Ioannou GN, Locke E, Green P, et al. Risk Factors for Hospitalization, Mechanical
253 254	4.	Ventilation, or Death Among $10\Box 131$ US Veterans With SARS-CoV-2 Infection. JAMA
254 255		<i>Netw Open</i> . 2020;3(9):e2022310.
255 256	5.	Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities,
250 257	5.	and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City
258		Area. Jama. 2020;323(20):2052-2059.
259	6.	Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress
260	0.	Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan,
261		China. JAMA Intern Med. 2020;180(7):934-943.
262	7.	Rambaut A, Holmes EC, O'Toole Á, et al. A dynamic nomenclature proposal for SARS-
262	7.	CoV-2 lineages to assist genomic epidemiology. <i>Nature Microbiology</i> . 2020;5(11):1403-
263 264		1407.
265	8.	Brufsky A. Distinct viral clades of SARS-CoV-2: Implications for modeling of viral
266		spread. Journal of Medical Virology. 2020;92(9):1386-1390.
267	9.	Korber B, Fischer WM, Gnanakaran S, et al. Tracking Changes in SARS-CoV-2 Spike:
268		Evidence that D614G Increases Infectivity of the COVID-19 Virus. <i>Cell</i> .
269		2020;182(4):812-827.e819.
270	10.	Lorenzo-Redondo R, Nam HH, Roberts SC, et al. A clade of SARS-CoV-2 viruses
271		associated with lower viral loads in patient upper airways. <i>EBioMedicine</i> . 2020;62.
272	11.	Plante JA, Liu Y, Liu J, et al. Spike mutation D614G alters SARS-CoV-2 fitness. Nature.
273		2021;592(7852):116-121.
274	12.	Weissman D, Alameh MG, de Silva T, et al. D614G Spike Mutation Increases SARS
275		CoV-2 Susceptibility to Neutralization. Cell Host Microbe. 2021;29(1):23-31.e24.
276	13.	Davies NG, Jarvis CI, Edmunds WJ, Jewell NP, Diaz-Ordaz K, Keogh RH. Increased
277		mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7. Nature. 2021.
278	14.	Katoh K, Standley DM. MAFFT Multiple Sequence Alignment Software Version 7:
279		Improvements in Performance and Usability. Molecular Biology and Evolution.
280		2013;30(4):772-780.
281	15.	Nicola De Maio* CW, Rui Borges, Lukas Weilguny, Greg Slodkowicz, Nick Goldman.
282		Masking strategies for SARS-CoV-2 alignments. https://virological.org/t/masking-
283		strategies-for-sars-cov-2-alignments/480. Published 2020. Accessed April 9, 2021.

- 16. Minh BQ, Schmidt HA, Chernomor O, et al. IQ-TREE 2: New Models and Efficient
 Methods for Phylogenetic Inference in the Genomic Era. *Molecular Biology and Evolution*. 2020;37(5):1530-1534.
- 287 17. People with Certain Medical Conditions. In: CDC, ed2021.
- 18. Ajufo E, Rao S, Navar AM, Pandey A, Ayers CR, Khera A. U.S. population at increased
 risk of severe illness from COVID-19. *Am J Prev Cardiol*. 2021;6:100156-100156.
- 290 19. Docherty AB, Harrison EM, Green CA, et al. Features of 20□133 UK patients in hospital
 291 with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective
 292 observational cohort study. *BMJ*. 2020;369:m1985-m1985.
- 293 20. Giorgi Rossi P, Marino M, Formisano D, et al. Characteristics and outcomes of a cohort
 294 of COVID-19 patients in the Province of Reggio Emilia, Italy. *PLoS One*.
 295 2020;15(8):e0238281-e0238281.
- 296 21. Kim L, Garg S, O'Halloran A, et al. Risk Factors for Intensive Care Unit Admission and
 297 In-hospital Mortality among Hospitalized Adults Identified through the U.S. Coronavirus
 298 Disease 2019 (COVID-19)-Associated Hospitalization Surveillance Network (COVID 299 NET). *Clin Infect Dis.* 2020:ciaa1012.
- Williamson EJ, Walker AJ, Bhaskaran K, et al. Factors associated with COVID-19 related death using OpenSAFELY. *Nature*. 2020;584(7821):430-436.
- 302 23. Bagchi S MJ, Li Q, et al. *MMWR Morb Mortal Wkly Rep 2021*. Rates of COVID-19
 303 Among Residents and Staff Members in Nursing Homes —
- 304 United States, May 25–November 22, 2020;70:52–55.
- 305 24. Garibaldi BT, Fiksel J, Muschelli J, et al. Patient Trajectories Among Persons
 306 Hospitalized for COVID-19 : A Cohort Study. *Ann Intern Med.* 2021;174(1):33-41.
- 25. Cardemil CV, Dahl R, Prill MM, et al. COVID-19-Related Hospitalization Rates and
 308 Severe Outcomes Among Veterans From 5 Veterans Affairs Medical Centers: Hospital309 Based Surveillance Study. *JMIR Public Health Surveill*. 2021;7(1):e24502-e24502.
- 310 26. Gold JAW, Wong KK, Szablewski CM, et al. Characteristics and Clinical Outcomes of
 311 Adult Patients Hospitalized with COVID-19 Georgia, March 2020. *MMWR Morb*312 *Mortal Wkly Rep.* 2020;69(18):545-550.
- Kabarriti R, Brodin NP, Maron MI, et al. Association of Race and Ethnicity With
 Comorbidities and Survival Among Patients With COVID-19 at an Urban Medical
 Center in New York. *JAMA network open.* 2020;3(9):e2019795-e2019795.
- Azar KMJ, Shen Z, Romanelli RJ, et al. Disparities In Outcomes Among COVID-19
 Patients In A Large Health Care System In California. *Health Aff (Millwood)*.
 2020;39(7):1253-1262.
- Hall WJ, Chapman MV, Lee KM, et al. Implicit Racial/Ethnic Bias Among Health Care
 Professionals and Its Influence on Health Care Outcomes: A Systematic Review. *Am J Public Health.* 2015;105(12):e60-e76.
- 322 30. Nelson A. Unequal treatment: confronting racial and ethnic disparities in health care. J
 323 Natl Med Assoc. 2002;94(8):666-668.
- 31. Harrison SL, Fazio-Eynullayeva E, Lane DA, Underhill P, Lip GYH. Comorbidities
 associated with mortality in 31,461 adults with COVID-19 in the United States: A
 federated electronic medical record analysis. *PLoS Med.* 2020;17(9):e1003321-e1003321.
- 327 32. Miyashita S, Yamada T, Mikami T, Miyashita H, Chopra N, Rizk D. Impact of dementia
- on clinical outcomes in elderly patients with coronavirus 2019 (COVID-19): an
 experience in New York. *Geriatr Gerontol Int.* 2020;20(7):732-734.

33. Hariyanto TI, Putri C, Arisa J, Situmeang RFV, Kurniawan A. Dementia and outcomes from coronavirus disease 2019 (COVID-19) pneumonia: A systematic review and meta-analysis. *Arch Gerontol Geriatr.* 2021;93:104299-104299.

332
333

Demographics		Comorbidities	
Age (years)	62.9+17.6	Immunosuppressed	10 (4)
Gender		Dementia	42 (15)
Male	254 (93)	Diabetes	68 (25)
Female	20 (7)	CKD 3	18 (7)
Race		Chronic liver disease	32 (12)
White	228 (83)	Chronic heart disease	107 (39)
Non-white	46 (17)	CAD	74 (27)
BMI > 30	110 (40)	Heart failure	29 (11)
From LTC	92 (34)	Atrial fibrillation	40 (15)
State		Chronic Lung disease	97 (35)
Connecticut	89 (32)	COPD	44 (16)
Massachusetts	150 (55)	Asthma	19 (7)
Maine	4 (1)	OSA	55 (20)
New Hampshire	9 (3)	Tobacco Use	62 (23)
Rhode Island	20 (7)		
Vermont	2(1)		

Results are presented as numbers (percentages).

335 Abbreviations: LTC - long term care, BMI – body mass index, CKD – chronic kidney disease,

336 CAD – coronary artery disease, COPD – chronic obstructive pulmonary disease, OSA –

obstructive sleep apnea

- 339 Table 1. Patient Characteristics (n=274)

Demographics	Hospitalization		Peak Severity		Death	
	Unadjusted OR (95% CI)	P-value	Unadjusted OR (95% CI)	P-value	Unadjusted OR (95% C.)	P-value
Age	1.06 (1.03-1.08)	<0.001*	1.06 (1.04 - 1.09)	< 0.001*	1.1 (1.06 - 1.14)	<0.001*
Gender			,		,	
Male	Ref		Ref		Ref	
Female	0.41 (0.12- 1.45)	0.17	0.42 (0.95 - 1.9)	0.26	n/a	n/a
Race	,					
White	Ref		Ref		Ref	
Non-White	1.97 (1.02 - 3.8)	0.04*	1.3 (0.6 - 2.6)	0.55	0.54 (0.16 - 1.9)	0.33
From Long Term Facility	1.78 (1.04 - 3.07)	0.04*	2.8 (1.5 - 5.1)	0.001*	7.9 (3.2 - 19.2)	<0.001*
Clinical Characteristics						
BMI < 30	1.52 (0.9 - 2.7)	0.14	1.1 (0.6 - 2)	0.77	5.8 (2.1 - 15.9)	0.001*
Dementia	0.63 (0.29 - 1.4)	0.25	1.6 (0.7 - 3.3)	0.26	7.2 (3.2 - 16.6)	<0.001*
COPD	3.04 (1.6 - 5.9)	0.001*	1.5 (0.74 - 3.2)	0.25	1.8 (0.7 - 4.5)	0.22
Heart Failure	1.6 (0.7 - 3.5)	0.25	1.8 (0.8 - 4.0)	0.18	1.9 (0.67 - 5.5)	0.23
CAD	2.93 (1.66 - 5.2)	<0.001*	2.1 (1.2 - 3.9)	0.016*	2.1 (0.9 - 4.6)	0.07
Atrial Fibrillation	2.05 (1.03 - 4.1)	0.04*	3 (1.4 - 5.9)	0.002*	3.1 (1.3 - 7.4)	0.01*
Hospitalization	n/a		n/a		2.58 (1.18- 5.65)	0.017*
O2 on admission	n/a		46.2 (19.9, 107.3)	<0.001*	4.34 (1.77 - 10.6)	0.001*

342 *p<0.05


343 Table 2. Univariate regression analysis of factors that predict hospitalization, peak severity,

344 and death

Demographics	Hospitalizati	ion	Peak Severit	У	Death	
9	OR (95%	P-	OR (95%	P-value	OR (95% C.I)	P-
	C.I)	value	C.I)			value
Age	1.05 (1.03,	<.001*	1.07 (1.03 -	< 0.001*	1.06 (1.01,	0.019*
	1.08)		1.11)		1.11)	
Race						
White	Ref		n/a		n/a	
Non-White	2.39 (1.13, 5.01)	0.021*				
From long term	0.70 (0.36,	0.307	1.18 (0.55,	0.668	2.0 (0.58,	0.273
facility	1.38)		2.55)		6.88)	
Clinical Characteristics						
BMI < 30	n/a		n/a		2.95 (0.81, 10.75)	0.102
Dementia	n/a		n/a		3.44 (1.07, 11.1)	0.038*
COPD	1.73 (0.84, 3.35)	0.136	n/a		n/a	
CAD	1.44 (0.75, 2.81)	0.273	0.71 (0.32, 1.55)	0.390	0.57 (0.209, 1.57)	0.283
Atrial Fibrillation	0.984 (0.45, 2.16)	0.969	1.11 (0.46, 2.64)	0.819	1.25 (0.42, 3.69)	0.686
Hospitalization	n/a		n/a		1.36 (0.40, 4.65)	0.631
O2 on admission	n/a		45.7 (18.79, 111)	<0.001*	6.74 (1.74, 26.1)	0.006*

348 Table 3. Multivariate regression analysis of factors that predict hospitalization, peak

349 severity, and death



- 352 Figure 1. Percent of patients hospitalized, based on patient demographics and
- 353 comorbidities





Figure 2. Percent of patients who died, based on patient demographics and comorbidities



- 360 Figure 3. Maximum Likelihood tree of genomes
- 363 Note: The authors would prefer color online only

Lineage	Count	Percent
A.1	3	1.0%
A.2	2	0.7%
A.3	2	0.7%
В	1	0.3%
B.1	154	51.5%
B.1.1.10	1	0.3%
B.1.1.113	1	0.3%
B.1.1.128	1	0.3%
B.1.1.163	1	0.3%
B.1.1.192	1	0.3%
B.1.1.225	1	0.3%
B.1.1.307	1	0.3%
B.1.104	4	1.3%
B.1.108	1	0.3%
B.1.110.3	1	0.3%
B.1.2	3	1.0%
B.1.243	1	0.3%
B.1.268	1	0.3%
B.1.280	2	0.7%
B.1.302	26	8.7%
B.1.313	19	6.4%
B.1.319	1	0.3%
B.1.320	1	0.3%
B.1.331	1	0.3%
B.1.356	18	6.0%
B.1.359	8	2.7%
B.1.36	1	0.3%
B.1.369	3	1.0%
B.1.382	1	0.3%
B.1.385	1	0.3%
B.1.390	16	5.4%
B.1.403	1	0.3%
B.1.413	1	0.3%

B.1.448	2	0.7%
B.1.448	1	0.3%
B.1.479	10	3.3%
B.1.509	2	0.7%
B.1.517	1	0.3%
B.1.521	1	0.3%
B.35	1	0.3%
N.1	1	0.3%